Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CKPTNASDAQ:KYTXNASDAQ:SNDLNASDAQ:TKNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCKPTCheckpoint Therapeutics$4.19+0.5%$4.08$1.75▼$4.50$350.97M1.181.28 million shs2.31 million shsKYTXKyverna Therapeutics$2.27-8.1%$2.12$1.78▼$16.64$98.11M2.17421,119 shs524,822 shsSNDLSNDL$1.29-1.5%$1.39$1.24▼$2.40$338.98M3.682.03 million shs1.27 million shsTKNOAlpha Teknova$5.97-4.2%$5.94$1.16▼$10.37$319.04M0.5393,518 shs398,237 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCKPTCheckpoint Therapeutics0.00%+0.96%+2.44%+33.87%+126.49%KYTXKyverna Therapeutics0.00%-2.16%+6.07%-18.35%-82.97%SNDLSNDL0.00%-4.44%-12.84%-27.12%-44.87%TKNOAlpha Teknova0.00%-9.68%-10.23%-19.87%+249.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCKPTCheckpoint Therapeutics2.0482 of 5 stars1.24.00.04.21.60.80.0KYTXKyverna Therapeutics2.1359 of 5 stars3.53.00.00.02.51.70.0SNDLSNDL3.066 of 5 stars3.53.00.00.03.00.01.3TKNOAlpha Teknova1.7075 of 5 stars3.51.00.00.02.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCKPTCheckpoint Therapeutics 2.33Hold$4.333.42% UpsideKYTXKyverna Therapeutics 3.00Buy$18.33707.64% UpsideSNDLSNDL 3.00Buy$3.63181.01% UpsideTKNOAlpha Teknova 3.00Buy$8.5042.38% UpsideCurrent Analyst Ratings BreakdownLatest KYTX, SNDL, TKNO, and CKPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $4.004/1/2025KYTXKyverna TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $20.003/31/2025CKPTCheckpoint TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.80 ➝ $4.803/19/2025SNDLSNDLATB CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price Target$3.50 ➝ $4.003/11/2025CKPTCheckpoint TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$4.103/10/2025CKPTCheckpoint TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $4.103/10/2025CKPTCheckpoint TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $4.80(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCKPTCheckpoint Therapeutics$41K8,560.27N/AN/A($0.47) per share-8.91KYTXKyverna Therapeutics$7.03M13.96N/AN/AN/A∞SNDLSNDL$927.61M0.37N/AN/A$3.47 per share0.37TKNOAlpha Teknova$38.25M8.34N/AN/A$2.21 per share2.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCKPTCheckpoint Therapeutics-$51.85M-$1.29N/A∞N/AN/AN/A-659.07%8/11/2025 (Estimated)KYTXKyverna Therapeutics-$60.37M-$3.38N/AN/AN/AN/A-51.12%-37.91%8/11/2025 (Estimated)SNDLSNDL-$127.91M-$0.29N/AN/AN/A-12.11%-8.27%-6.96%8/7/2025 (Estimated)TKNOAlpha Teknova-$36.78M-$0.48N/AN/AN/A-87.17%-35.30%-24.52%N/ALatest KYTX, SNDL, TKNO, and CKPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CKPTCheckpoint Therapeutics-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A5/13/2025Q1 2025KYTXKyverna Therapeutics-$1.21-$1.03+$0.18-$1.03N/AN/A5/8/2025Q1 2025TKNOAlpha Teknova-$0.11-$0.09+$0.02-$0.09$9.41 million$9.60 million5/1/2025Q1 2025SNDLSNDL-$0.06-$0.04+$0.02-$0.04$214.60 million$142.38 million3/28/2025Q4 2024CKPTCheckpoint Therapeutics-$0.22-$0.69-$0.47-$0.69N/A$0.04 million3/27/2025Q4 2024KYTXKyverna Therapeutics-$0.87-$0.88-$0.01-$0.88N/AN/A3/18/2025Q4 2024SNDLSNDL-$0.01-$0.19-$0.18-$0.19$248.10 million$179.06 million3/4/2025Q4 2024TKNOAlpha TeknovaN/A-$0.11N/A-$0.11$9.10 million$9.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCKPTCheckpoint TherapeuticsN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCKPTCheckpoint TherapeuticsN/A0.290.29KYTXKyverna TherapeuticsN/A10.5010.50SNDLSNDL0.105.614.16TKNOAlpha Teknova0.124.733.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCKPTCheckpoint Therapeutics22.00%KYTXKyverna Therapeutics18.08%SNDLSNDLN/ATKNOAlpha Teknova13.81%Insider OwnershipCompanyInsider OwnershipCKPTCheckpoint Therapeutics2.10%KYTXKyverna Therapeutics22.00%SNDLSNDLN/ATKNOAlpha Teknova15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCKPTCheckpoint Therapeutics1083.76 million47.81 millionOptionableKYTXKyverna Therapeutics9643.22 millionN/AOptionableSNDLSNDL580262.78 millionN/AOptionableTKNOAlpha Teknova24053.44 million45.21 millionNot OptionableKYTX, SNDL, TKNO, and CKPT HeadlinesRecent News About These CompaniesOMERS ADMINISTRATION Corp Makes New Investment in Alpha Teknova, Inc. (NASDAQ:TKNO)May 22 at 4:23 AM | marketbeat.comAlpha Teknova, Inc. (NASDAQ:TKNO) Stake Reduced by Schonfeld Strategic Advisors LLCMay 17, 2025 | marketbeat.comSusquehanna International Group LLP Buys 172,828 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO)May 13, 2025 | marketbeat.comAlpha Teknova (NASDAQ:TKNO) Posts Earnings ResultsMay 12, 2025 | marketbeat.comAlpha Teknova, Inc. (NASDAQ:TKNO) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comAlpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comRaymond James Financial Inc. Invests $716,000 in Alpha Teknova, Inc. (NASDAQ:TKNO)May 9, 2025 | marketbeat.comTeknova Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.com683 Capital Management LLC Acquires New Shares in Alpha Teknova, Inc. (NASDAQ:TKNO)May 4, 2025 | marketbeat.com65,036 Shares in Alpha Teknova, Inc. (NASDAQ:TKNO) Purchased by Apollo Management Holdings L.P.May 2, 2025 | marketbeat.comAlpha Teknova (TKNO) Traded Lower on Increased UncertaintyApril 30, 2025 | msn.comInvesco Ltd. Invests $9.24 Million in Alpha Teknova, Inc. (NASDAQ:TKNO)April 26, 2025 | marketbeat.comAlpha Teknova, Inc. to Report First Quarter Financial Results on May 8, 2025April 24, 2025 | quiverquant.comTeknova to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | globenewswire.comAlpha Teknova, Pluristyx launch proprietary PluriFreeze cryopreservation systemMarch 20, 2025 | markets.businessinsider.comTeknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell TherapiesMarch 19, 2025 | markets.businessinsider.comTeknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell TherapiesMarch 19, 2025 | globenewswire.comTeknova, Pluristyx announce collaboration over next-generation cell therapiesMarch 11, 2025 | markets.businessinsider.comTeknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell TherapiesMarch 11, 2025 | globenewswire.comEarnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.67March 8, 2025 | uk.finance.yahoo.comBTIG Reaffirms Their Hold Rating on Alpha Teknova (TKNO)March 6, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKYTX, SNDL, TKNO, and CKPT Company DescriptionsCheckpoint Therapeutics NASDAQ:CKPT$4.19 +0.02 (+0.48%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.18 -0.01 (-0.12%) As of 05/23/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Kyverna Therapeutics NASDAQ:KYTX$2.27 -0.20 (-8.10%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.26 -0.01 (-0.44%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.SNDL NASDAQ:SNDL$1.29 -0.02 (-1.53%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.28 -0.01 (-0.39%) As of 05/23/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.Alpha Teknova NASDAQ:TKNO$5.97 -0.26 (-4.17%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.99 +0.02 (+0.34%) As of 05/23/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Alphabet Stock Lags—But Waymo May Be Its Hidden Driver This Market Sell-Off Might Trigger a Value Rotation Into Pepsi Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
